Page last updated: 2024-12-05

dimethyldioctadecylammonium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dimethyldioctadecylammonium (DODA) is a quaternary ammonium cation, also known as dioctadecyldimethylammonium. It is a surfactant, and its bromide salt, dioctadecyldimethylammonium bromide (DODAB), is commonly used in research and applications. DODA is a cationic surfactant, meaning it has a positively charged head group and a long hydrophobic tail. Its properties make it useful in various applications, including drug delivery, gene therapy, and biomaterial engineering. It is also studied for its effects on cell membranes, its ability to form micelles, and its use in self-assembly processes. DODA's surfactant properties and ability to interact with biological membranes make it a valuable tool in various fields, such as biophysics, materials science, and nanotechnology.'
```

dimethyldioctadecylammonium: a cationic lipid analog; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7880
SCHEMBL ID30485
MeSH IDM0065383

Synonyms (21)

Synonym
ddbas compound
ammonium, dimethyldioctadecyl-
1-octadecanaminium, n,n-dimethyl-n-octadecyl-
dioctadecyldimethylammonium ion
dimethyldioctadecylammonium
n,n-dimethyl-n-octadecyl-1-octadecanaminium
dimethyl(dioctadecyl)azanium
ogqyppbgslzbeg-uhfffaoysa-
dimethyl-dioctadecylazanium bromide
inchi=1/c38h80n/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h5-38h2,1-4h3/q+1
14357-21-2
251iw5i21c ,
unii-251iw5i21c
dimethyldistearylammonium
distearyldimethylammonium
dioctadecyldimethylammonium
distearyldimonium
SCHEMBL30485
DB14143
Q27253895
DTXSID00859191

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" At low drug to lipid molar ratios, hepatotoxicity, spleen damage and blood changes in comparison to DOC/AMB (sodium desoxycholate/amphotericin B, Fungizone) are evaluated ultimately showing toxic effects associated to DODAB only."( Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio.
Borelli, P; Carmona-Ribeiro, AM; Fock, R; Lincopan, N; Mamizuka, EM, 2006
)
0.33
" Comprehensive toxicity studies of the CAF01 adjuvant-alone and together with different vaccines showed that CAF01 when tested at human dose levels was safe and well tolerated with only local inflammation at the site of injection and no systemic reactions."( Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Andersen, P; Andreasen, LV; Bang, P; Fomsgaard, A; Gram, G; Karlsson, I; Kromann, I; Schou, C; Tang, S, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
" Therefore the aim of this study was to investigate the impact of a combination of reduced vesicle size and surface pegylation on the biodistribution and adjuvanticity of the formulations, in a bid to further manipulate the pharmacokinetic profiles of these adjuvants."( Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
Bramwell, VW; Kaur, R; Kirby, DJ; Perrie, Y, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" The enhanced immune response was dependent on DDA dosage and was most striking when DDA was directly complexed to the IAD-treated cells."( Enhanced response to chemoimmunotherapy and immunoprophylaxis with the use of tumor-associated antigens with a lipophilic agent.
Gordon, WC; Prager, MD, 1978
)
0.26
" Dose-response curves of both antigen and adjuvant revealed that DXS compared to DDA is a more effective adjuvant for the induction of a humoral response to SRBC."( Immunomodulating properties of two synthetic adjuvants: dependence upon type of antigen, dose, and time of administration.
Hilgers, LA; Jansze, M; Snippe, H; Willers, JM, 1984
)
0.27
" Dose-response curves for DH and humoral antibody responses to EMC virus were not concordant."( Effect of the adjuvant dimethyl dioctadecyl ammonium bromide on the humoral and cellular immune responses to encephalomyocarditis virus.
Benaissa-Trouw, BJ; Harmsen, T; Jansen, J; Kraaijeveld, CA; la Rivière, G; Snippe, H, 1983
)
0.27
" The results from this study can be applied as a model for the development of a gene-therapeutic dosage form."( Expression of luciferase plasmid (pCMVLuc) entrapped in DPPC/cholesterol/DDAB liposomes in HeLa cell lines.
Manosroi, A; Manosroi, J; Peschka-Süss, R; Schubert, R; Thathang, K; Werner, RG, 2009
)
0.35
" saRNA has been shown to induce protein expression for up to 60 days and elicit immune responses with lower dosing than messenger RNA (mRNA)."( Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA.
Aldon, Y; Blakney, AK; McKay, PF; Shattock, RJ; Yus, BI, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (344)

TimeframeStudies, This Drug (%)All Drugs %
pre-199039 (11.34)18.7374
1990's35 (10.17)18.2507
2000's124 (36.05)29.6817
2010's134 (38.95)24.3611
2020's12 (3.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.06 (24.57)
Research Supply Index5.87 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index45.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (1.98%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other346 (98.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]